NCT01890109View on ClinicalTrials.gov

Study of Erenumab (AMG 334) in Women With Hot Flashes

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

May 13, 2013

Primary Completion Date

March 11, 2014

Study Completion Date

March 11, 2014

Conditions
Vasomotor Symptoms; Hot Flashes
Interventions
BIOLOGICAL

Erenumab

Administered via subcutaneous injection.

DRUG

Placebo

Administered via subcutaneous injection

Trial Locations (7)

19114

Eugene Andruczyk, Philadelphia

Research Site, Philadelphia

27103

Research Site, Winston-Salem

29464

Research Site, Mt. Pleasant

33186

Research Site, Miami

92108

Research Site, San Diego

98105

Research Site, Seattle

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01890109 - Study of Erenumab (AMG 334) in Women With Hot Flashes | Biotech Hunter | Biotech Hunter